Spotlight On Sarepta Post-BioMarin Duchenne Rejection

It was highly likely the FDA was going to turn down BioMarin Pharmaceutical Inc. on its Duchenne muscular dystrophy (DMD) drug Kyndrisa (drisapersen), given the beating it took this past November at the meeting of the agency's Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee and the fact regulators had earlier called the firm's data "inconsistent," and in some cases, "contradictory."

It was highly likely the FDA was going to turn down BioMarin Pharmaceutical Inc. on its Duchenne muscular dystrophy (DMD) drug Kyndrisa (drisapersen), given the beating it took this past November at the meeting of the agency's Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee and the fact regulators had earlier called the firm's data "inconsistent," and in some cases, "contradictory."

BioMarin investors were prepared for the bad news, and at first blush, even pushed shares of the company up 3.2%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Musculoskeletal

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

More from Therapy Areas

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

Boehringer Scores First Approval For Targeted Oral Drug In HER2-Mutant NSCLC

 

The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

 

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.